BDBM435010 US10584114, Compound 130::US11279688, Compound 130

SMILES CO[C@@]1(CC[C@@H](CC1)c1nc(C)cc(Nc2cc(C)[nH]n2)n1)C(=O)N[C@@H](C)c1ccc(nc1)-n1cc(F)cn1

InChI Key

Data  13 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 13 hits for monomerid = 435010   

TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50: <500nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50: <500nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HEPES...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  0.780nMAssay Description:Inhibition of RET wild type (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  1.90nMAssay Description:Inhibition of RET V804M mutant (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  0.700nMAssay Description:Inhibition of RET M918T mutant (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Guangzhou Baiyunshan Pharmaceutical Holdings

Curated by ChEMBL
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  2nMAssay Description:Inhibition of JAK2 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  2.40nMAssay Description:Inhibition of wild type rearranged during transfection kinase (unknown origin) preincubated for 1 hr followed by addition of development agent incuba...More data for this Ligand-Target Pair
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of wild type RET (ProQinase 1090-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HE...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804L](Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50: <10nMAssay Description:In each well of a 384-well plate, 7.5 nM-10 nM of mutant RET (ProQinase 1096-0000-1) was incubated in a total of 12.5 μL of buffer (100 mM HEPES...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human wild type RETMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  0.300nMAssay Description:Inhibition of human RET V804L mutantMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Blueprint Medicines

US Patent
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  0.400nMAssay Description:Inhibition of human RET V804M mutantMore data for this Ligand-Target Pair
In DepthDetails PubMed
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Guangzhou Baiyunshan Pharmaceutical Holdings

Curated by ChEMBL
LigandPNGBDBM435010(US10584114, Compound 130 | US11279688, Compound 13...)
Affinity DataIC50:  6.5nMAssay Description:Inhibition of FLT3 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed